And more ASCO GU 2024 phase 3 trial

[Maxone73]

Data will be presented at ASCO GU 2024 but looks promising

"In combination with immunotherapy, Cabometyx is delivering long-term survival benefits today for people living with renal cell carcinoma worldwide, while also showcasing future potential in metastatic castration-resistant prostate cancer, an area of significant unmet need where no other trials of this modality have proven successful in recent decades," said Christelle Huguet, Ipsen's executive vice president and head of research and development.

marketwatch.com/story/ipsen...